Literature DB >> 19364867

Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.

Patrizia Spigaglia1, Fabrizio Barbanti, Thomas Louie, Frédéric Barbut, Paola Mastrantonio.   

Abstract

Recent studies have suggested that exposure to fluoroquinolones represents a risk factor for the development of Clostridium difficile infections and that the acquisition of resistance to the newer fluoroquinolones is the major reason facilitating wide dissemination. In particular, moxifloxacin (MX) and levofloxacin (LE) have been recently associated with outbreaks caused by the C. difficile toxinotype III/PCR ribotype 027/pulsed-field gel electrophoresis type NAP1 strain. In this study, we evaluated the potential of MX and LE in the in vitro development of fluoroquinolone resistance mediated by GyrA and GyrB alterations. Resistant mutants were obtained from five C. difficile parent strains, susceptible to MX, LE, and gatifloxacin (GA) and belonging to different toxinotypes, by selection in the presence of increasing concentrations of MX and LE. Stable mutants showing substitutions in GyrA and/or GyrB were obtained from the parent strains after selection by both antibiotics. Mutants had MICs ranging from 8 to 128 microg/ml for MX, from 8 to 256 microg/ml for LE, and from 1.5 to > or = 32 microg/ml for GA. The frequency of mutation ranged from 3.8 x 10(-6) to 6.6 x 10(-5) for MX and from 1.0 x 10(-6) to 2.4 x 10(-5) for LE. In total, six different substitutions in GyrA and five in GyrB were observed in this study. The majority of these substitutions has already been described for clinical isolates or has occurred at positions known to be involved in fluoroquinolone resistance. In particular, the substitution Thr82 to Ile in GyrA, the most common found in resistant C. difficile clinical isolates, was observed after selection with LE, whereas the substitution Asp426 to Val in GyrB, recently described in toxin A-negative/toxin B-positive epidemic strains, was observed after selection with MX. Interestingly, a reduced susceptibility to fluoroquinolones was observed in colonies isolated after the first and second steps of selection by both MX and LE, with no substitution in GyrA or GyrB. The results suggest a relevant role of fluoroquinolones in the emergence and selection of fluoroquinolone-resistant C. difficile strains also in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19364867      PMCID: PMC2687229          DOI: 10.1128/AAC.01252-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Mutation in the DNA gyrase A Gene of Escherichia coli that expands the quinolone resistance-determining region.

Authors:  S M Friedman; T Lu; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Confirmed cases and report of clusters of severe infections due to Clostridium difficile PCR ribotype 027 in Germany.

Authors:  N Kleinkauf; B Weiss; A Jansen; T Eckmanns; B Bornhofen; E Küehnen; H-P Weil; H Michels
Journal:  Euro Surveill       Date:  2007-11-15

3.  First confirmed cases of Clostridium difficile PCR ribotype 027 in Norway.

Authors:  A Ingebretsen; G Hansen; C Harmanus; E J Kuijper
Journal:  Euro Surveill       Date:  2008-01-10

4.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

5.  Detection of gyrA mutations in quinolone-resistant Salmonella enterica by denaturing high-performance liquid chromatography.

Authors:  Deborah J Eaves; Ernesto Liebana; Martin J Woodward; Laura J V Piddock
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

6.  Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations.

Authors:  H Wang; J L Dzink-Fox; M Chen; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

7.  Characterization of fluoroquinolone resistance mechanisms and their correlation with the degree of resistance to clinically used fluoroquinolones among Escherichia coli isolates.

Authors:  Tsung-Ming Chang; Po-Liang Lu; Hsuan-Hui Li; Chung-Yu Chang; Tun-Chieh Chen; Lin-Li Chang
Journal:  J Chemother       Date:  2007-10       Impact factor: 1.714

8.  Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates.

Authors:  F Barbut; P Mastrantonio; M Delmée; J Brazier; E Kuijper; I Poxton
Journal:  Clin Microbiol Infect       Date:  2007-09-11       Impact factor: 8.067

Review 9.  Emerging mechanisms of fluoroquinolone resistance.

Authors:  D C Hooper
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883

10.  gyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027.

Authors:  Denise Drudy; Lorraine Kyne; Rebecca O'Mahony; Séamus Fanning
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

View more
  12 in total

1.  In vivo selection of moxifloxacin-resistant Clostridium difficile.

Authors:  Ana Mena; Elena Riera; Carla López-Causapé; Irene Weber; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

Review 2.  The changing epidemiology of Clostridium difficile infections.

Authors:  J Freeman; M P Bauer; S D Baines; J Corver; W N Fawley; B Goorhuis; E J Kuijper; M H Wilcox
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

Review 3.  Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection.

Authors:  Patrizia Spigaglia
Journal:  Ther Adv Infect Dis       Date:  2016-02

4.  Predominance and high antibiotic resistance of the emerging Clostridium difficile genotypes NAPCR1 and NAP9 in a Costa Rican hospital over a 2-year period without outbreaks.

Authors:  Diana López-Ureña; Carlos Quesada-Gómez; Mónica Montoya-Ramírez; María del Mar Gamboa-Coronado; Teresita Somogyi; César Rodríguez; Evelyn Rodríguez-Cavallini
Journal:  Emerg Microbes Infect       Date:  2016-05-11       Impact factor: 7.163

5.  The SOS Response Master Regulator LexA Is Associated with Sporulation, Motility and Biofilm Formation in Clostridium difficile.

Authors:  Beata M Walter; Stephen T Cartman; Nigel P Minton; Matej Butala; Maja Rupnik
Journal:  PLoS One       Date:  2015-12-18       Impact factor: 3.240

6.  Clostridium difficile in patients attending tuberculosis hospitals in Cape Town, South Africa, 2014-2015.

Authors:  Brian R Kullin; Sharon Reid; Valerie Abratt
Journal:  Afr J Lab Med       Date:  2018-12-06

7.  Antimicrobial susceptibility profiles of human and piglet Clostridium difficile PCR-ribotype 078.

Authors:  Elisabeth C Keessen; Marjolein Pm Hensgens; Patrizia Spigaglia; Fabrizio Barbanti; Ingrid Mjg Sanders; Ed J Kuijper; Len Ja Lipman
Journal:  Antimicrob Resist Infect Control       Date:  2013-04-08       Impact factor: 4.887

Review 8.  Mechanisms of antibiotic resistance of Clostridioides difficile.

Authors:  Ishani Wickramage; Patrizia Spigaglia; Xingmin Sun
Journal:  J Antimicrob Chemother       Date:  2021-11-12       Impact factor: 5.758

9.  Antimicrobial susceptibility and molecular characterization of macrolide resistance of Mycoplasma bovis isolates from multiple provinces in China.

Authors:  Ling-Cong Kong; Duo Gao; Bo-Yan Jia; Zi Wang; Yun-Hang Gao; Zhi-Hua Pei; Shu-Ming Liu; Jiu-Qing Xin; Hong-Xia Ma
Journal:  J Vet Med Sci       Date:  2015-09-07       Impact factor: 1.267

10.  CD2068 potentially mediates multidrug efflux in Clostridium difficile.

Authors:  Chawalit Ngernsombat; Suthasinee Sreesai; Phurt Harnvoravongchai; Surang Chankhamhaengdecha; Tavan Janvilisri
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.